Unique collaboration pairs HLT’s data technology and artificial
intelligence with PPD’s global expertise in clinical trials and
real-world evidence generation
WILMINGTON, N.C. & BEIJING–(BUSINESS WIRE)–Pharmaceutical Product Development, LLC (PPD)
and Happy Life Tech (HLT)
of China have signed an exclusive agreement to develop a distinctive
service offering for the China drug-development market delivering data
science-driven clinical trials and real-world evidence of drug products’
effectiveness, safety and value.
The strategic collaboration is designed to enhance global pharmaceutical
companies’ access to China’s evolving drug development and
post-marketing ecosystem to address unmet clinical needs in China, while
enhancing research capabilities for the Chinese pharmaceutical industry
in the global market. The combined service offerings are powered by
HLT’s artificial intelligence (AI) and data technology and PPD’s global
expertise in clinical trial management and evidence generation.
HLT contributes an unparalleled ability to generate AI-enabled solutions
and its growing network of prominent physicians and more than 100
leading hospitals in 22 Chinese provinces. Capitalizing on PPD’s global
clinical research resources and China footprint, the collaboration
intends to provide pharmaceutical and biotechnology clients with
unsurpassed services in China, including clinical study protocol design,
site selection, patient recruitment and real-world evidence.
“Our collaboration with HLT will provide PPD’s clients with exciting new
opportunities in China,” said David Simmons, chairman and chief
executive officer of PPD. “Our focus on sites with access to eligible
patients is designed to speed patient recruitment at high-performing
sites and to more effectively incorporate Chinese patients into global
trials. We will help clients adapt study protocols to the China market,
while helping sites enhance quality, drive performance and lead global
multicenter trials. In addition, we will intelligently leverage
real-world data in China to recruit patients with a high potential for
participation in our clients’ studies and to generate real-world
insights needed for market access and product uptake.”
Rujing Gong, founder of HLT, said, “I am very excited about this
collaboration. We believe a joint effort between PPD and HLT will
empower our clients with unique solutions, significantly increase trial
efficiency, reduce costs and ultimately benefit patients in China and
around the world. We’ll also help the Chinese pharma industry be more
competitive in the global market through a better registration strategy.
China’s research capability has been developing quickly and will play an
important role in the global clinical development market in the future.
We have strong interest in being involved and in driving the process.”
The companies’ exclusive collaboration focuses on data-driven
feasibility, patient recruitment and real-world evidence offerings for
both global and China-based pharmaceutical and biotech companies.
PPD has nearly 20 years of extensive experience in Asia-Pacific and
provides a broad range of Phase I-IV services in the region. The
company’s global capabilities include clinical trial operations based in
Beijing and Shanghai and central laboratory facilities in Shanghai.
PPD’s Evidera business unit is the preeminent provider of evidence-based
solutions to demonstrate the real-world effectiveness, safety and value
of biopharmaceutical and biotechnology products from early development
through loss of exclusivity.
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 48 countries and more than 21,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.
HLT is a leading medical AI company dedicated to transforming the
relationship between humans and diseases. HLT has in-depth cooperation
with regulators, universities and research institutes in China and other
countries. Full lifecycle solutions of HLT, including clinical trials,
post-launch development of drugs, product launch and real-world studies,
significantly accelerate the process of new drug development. In
addition, HLT’s reports based on real-world insights have been published
in The Lancet Oncology, Nature Medicine and other top
journals. For more information, visit https://www.hltpharma.com/en-index.html.
+1 919 456
+1 910 558 6783
Media and Consultancy:
+86 10 84867197